Next Article in Journal
A Biflavonoid-Rich Extract from Selaginella doederleinii Hieron. against Throat Carcinoma via Akt/Bad and IKKβ/NF-κB/COX-2 Pathways
Next Article in Special Issue
The Use of Triphenyl Phosphonium Cation Enhances the Mitochondrial Antiplatelet Effect of the Compound Magnolol
Previous Article in Journal
New Derivatives of the Multi-Stage Active Malaria Box Compound MMV030666 and Their Antiplasmodial Potencies
Previous Article in Special Issue
Modulation of Cytoskeleton, Protein Trafficking, and Signaling Pathways by Metabolites from Cucurbitaceae, Ericaceae, and Rosaceae Plant Families
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Xanthium spinosum L. Extracts Inhibit Breast Cancer in Mice by Apoptosis Induction and Immune System Modulation

1
Department of Health Sciences, College of Natural and Health Sciences, Zayed University, Abu Dhabi 144534, United Arab Emirates
2
Department of Clinical Pharmacy and Therapeutics, Applied Science Private University, Amman 11931-166, Jordan
3
Faculty of Allied Medical Sciences, Applied Science Private University, Amman 11931-166, Jordan
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2022, 15(12), 1504; https://doi.org/10.3390/ph15121504
Submission received: 11 October 2022 / Revised: 26 November 2022 / Accepted: 28 November 2022 / Published: 2 December 2022

Abstract

:
Plants have been considered for many years as an important source of medicine to treat different diseases. Xanthium spinosum L. (Asteraceae, Compositae) is known for its diuretic, anti-inflammatory, and sedative effects. It is also used in the treatment of several ailments, such as cancer. In order to evaluate the anticancer and immunomodulatory activities, crude ethanol extract was prepared from the aerial part of X. spinosum and then fractionated using solvents with different polarities. As well, the chemical composition of X. spinosum extract and fractions were identified using LC-MS analysis. The antitumor effect of X. spinosum was assessed in both in vitro and in vivo models. Apoptosis induction was measured in vitro using a caspase-3 activity kit. Lymphocyte proliferation and phagocytosis and pinocytosis induction were used to quantify the effect of the plant extract and fractions on acquired and innate immunity, respectively. The effect of X. spinosum extract, and fractions on the levels of cytokines (IFN-γ, IL-2, IL-4, and IL-10) in murine lymphocytes was determined using a mouse-uncoated TH1/TH2 ELISA kit. Results showed that ethanol extract had the highest antiproliferative activity (IC₅₀ = 2.5 mg mL−1) against EMT6/P cell lines, while the aqueous and chloroform fractions had the highest apoptotic activity with 2.2 and 1.7 folds, respectively. On the other hand, the n-hexane fraction was the most effective in stimulating lymphocyte proliferation, whereas ethanol extract, aq. Methanol and aqueous fractions exhibited the highest phagocytic activity. As well, X. spinosum extract and fractions were able to modulate the expression of IL-2, IL-4, and IFN-γ. A remarkable decrease in tumor size was accomplished following the treatment of tumor-bearing mice with X. spinosum extract and fractions. Both aq. Methanol and chloroform fractions showed the highest percentage change in tumor size with -58 and -55%, respectively. As well, tumor-bearing mice treated with chloroform fraction demonstrated a high curable percentage with a value of 57.1%. Anyway, X. spinosum extract and fractions exhibited no toxic impact on the liver or kidney functions of the mice-treated groups. These findings may confirm that X. spinosum has favorable anticancer and immunomodulatory effects. However, additional studies are required to fully understand the mechanisms of action of this plant and the signaling pathways involved in its effects. Moreover, more testing is needed to have better insight into the apoptotic pathway and to know the exact concentration of active compounds.

1. Introduction

Cancer is among the main causes of death, responsible for one in eight deaths worldwide [1]. Cancer deaths are estimated to reach up to 11.5 million in 2030 [2]. Chemotherapy, one of the most common treatments routinely used for cancer, is not devoid of side effects and intrinsic problems [3]. Furthermore, many therapeutic agents have little impact on survival rates. Other treatment options for cancer include surgery and radiation therapy which also have limitations and side effects [4]. Regardless of the successes in treating and managing cancer, the need for more effective anticancer agents that have fewer side effects remains crucial.
Significant scientific evidence shows the importance of medicinal plants in the development of new drugs to treat different diseases. A total of 35,000 plant species have been screened by the National Cancer Institute (NCI) for their anticancer potential. Approximately, 25% of all prescriptions contain a minimum of one active ingredient obtained from medicinal plants [5]. The species X. spinosum L. (Asteraceae, Compositae) is a member of the subtribe Ambrosiinae (Heliantheae) [6]. The plant is indigenous to South America, but it is widely distributed in different parts of the world, including the Mediterranean region [7]. X. spinosum L. is a source of many flavonoids, including quercetin, iocein, centaurin, pendulin, and patuletin 3-O-glucoside [8]. In addition, several xanthanolide sesquiterpene lactones, such as xanthatin, xanthinin, stizolicin, and solstitialin are found in this plant [9]. X. spinosum has been recognized in traditional medicine for its antibacterial [10], antiviral [11], anti-inflammatory [12], and sedative [13] properties. Different plant parts have been used to cure cancer, diarrhea [8,14], rabies [15], and rheumatoid arthritis [16]. Despite the scarcity of available data on the biological and pharmacological effects of X. spinosum, the chemical analysis identified a high number of monoterpenes and sesquiterpenes, many of which are known for their antioxidant and anticancer properties [17]. In light of the traditional use of the plant, the current work aimed to explore the anticancer and immunomodulatory activities of X. spinosum.

2. Results

2.1. LC-MS Analysis of X. Spinosum Ethanol Extract

The result of LC-MS analysis showed that ethanol extract, chloroform, and n-hexane fractions were rich in eupatilin, with a relative percentage among detected compounds of 89.8%, 76.8%, and 85.5%, respectively (Table 1, Table 2 and Table 3). On the other hand, aqueous and aq. Methanol fractions revealed the presence of apiin at percentage values of 39% and 31%, respectively (Table 4 and Table 5). Acteoside (48.3%) was found abundantly in aq. Methanol fraction, while genistein (19.8%) and kaempferide (19%) were prominently found in aqueous fraction (Table 4 and Table 5).

2.2. Antiproliferative Activity of X. spinosum Extract and Fractions

Based on MTT results, X. spinosum extract and fractions exhibited cytotoxic activity against T47D, MCF-7, and EMT6/P cell lines (Figure 1). The ethanol extract was more cytotoxic against EMT6/P compared to T47D and MCF-7 cell lines with an IC₅₀ of 2.57 mg mL−1 (Table 6). In the MCF-7 cell line, aqueous and n-hexane fractions were able to reduce cell growth effectively with IC₅₀ values of 4.78 and 4.29 mg mL−1, respectively. X. spinosum extract and fractions showed a higher percentage of survival in normal cells (Vero cells) compared to the tumor cells (Figure 1D).

2.3. Apoptotic Activity of X. spinosum Extract and Fractions against EMT6/P Cell Line

Apoptosis is controlled by many factors, and one of the main players in this process is caspase-3 protein. In order to detect this apoptotic marker, a caspase-3 assay kit was utilized. Based on the results, the aqueous fraction significantly (p < 0.001) showed the highest fold enhancement in caspase-3 activity (2.25 folds), followed by the chloroform fraction (1.72 folds) (Figure 2). However, aq. Methanol fraction showed the lowest effect on the activity of caspase-3 (1.25 folds) compared to the negative control.

2.4. Toxicity Evaluation of X. spinosum Extract and Fractions

The LD₅₀ was detected based on the arithmetical method of Karber. There was diversity in the mortality of mice within the three groups (Table 7 and Table 8). The estimated LD₅₀ of X. spinosum extract and fractions were as the following: ethanol (1959 mg kg−1), aqueous, and aq. Methanol fraction (2709 mg kg−1), chloroform (219 mg kg−1), and n-hexane (167 mg kg−1) (Table 7 and Table 8). It is worth mentioning that choosing starting doses were based on a pilot study conducted previously, which revealed a notable safety of the polar extract and fractions. As a result, the preliminary therapeutic dose for the in vivo treatment was 1/10 of the LD₅₀ value for X. spinosum extract and fractions.

2.5. Antitumor Effects of X. spinosum Extract and Fractions on EMT6/P Cells Implanted in Mice

The in vivo experiment showed a significant (p < 0.05) decrease in tumor size (percentage between -58 and -29) compared to the negative control (108.5) (Table 9 and Figure 3). The chloroform fraction-treated group showed 57.1% of mice with no detectable tumor, while the percentage in the control group was 22.2% (Table 9). In addition, there was a difference in the average tumor weight of both groups (Table 9 and Figure 4). Based on the daily observation, mice showed normal activity with no side effects upon treating them with X. spinosum extract and fractions.

2.6. Effect of X. spinosum Extract and Fractions on Serum Levels of ALT, AST, and Creatinine

Treating mice with X. spinosum extract and fractions exhibited no effect on the serum level of creatinine (Figure 5A). As well it showed an insignificant (p > 0.05) change in ALT and AST serum levels compared to the control group (Figure 5B).

2.7. Effect of X. spinosum Extract and Fractions on Lymphocytes Proliferation in the Presence and Absence of Mitogens

Lymphocyte proliferation was slightly stimulated when treated with X. spinosum extract and fractions. As a matter of effectiveness, the n-hexane fraction showed the highest stimulation index in both conditions, with or without co-mitogen (stimulation index between 3.27 and 1.74) (Figure 6). At the higher tested concentration (100 mg mL−1), the chloroform fraction exhibited activity parallel to the n-hexane fraction with a stimulation index range between 2.7 and 1.58 (Figure 6).

2.8. Effect of X. spinosum Extract and Fractions on Phagocytic Activity of Mouse Peritoneal Macrophages

The results of this experiment have shown an improvement in the phagocytic effect of murine macrophages. At concentration of 100 mg mL−1, aq. methanol fraction, followed by ethanol extract and aqueous fraction, exhibited the highest activity with a phagocytic index between 171 and 152 (Figure 7). However, the n-hexane fraction showed a lower phagocytic index compared to the other X. spinosum-tested samples.

2.9. Effect of X. spinosum Extract and Fractions on the Pinocytic Activity of Mouse Peritoneal Macrophages

Both n-hexane and chloroform fractions displayed a slight stimulation of murine macrophage pinocytic activity. At the higher tested concentrations, their pinocytic index values were 263 and 218, respectively (Figure 8).

2.10. Effect of X. spinosum Extract and Fractions on Cytokines of Murine Splenic Lymphocytes

The concentration of cytokines (IFN-γ, IL-2, IL-4, and IL-10) was determined using a mouse-uncoated TH1/TH2 ELISA kit. Based on the results, X. spinosum extract and fractions were significantly (p < 0.05) able to modulate interleukins expression compared to the negative control (Figure 9). Chloroform fraction and ethanol extract showed an effect on IL-2 with a concentration of 394 and 384 pg mL−1 compared to the negative control (186 pg mL−1) (Figure 9).

3. Discussion

Cancer is a serious global health issue and the main cause of mortality responsible for millions of deaths all over the world every year. It is expected that cancer cases will reach up to 24 million in 2030 [18]. Despite the progress in cancer research and therapeutic advancements over the past decade, there remains a need to further investigate potential anti-cancer agents.
Natural products have been long considered an origin of chemical diversity, providing the ground for the identification of promising new anticancer agents that may exhibit high efficiency and low toxicity. X. spinosum has been utilized in traditional medicine as a remedy for many different conditions. For example, the leaves and fruits were used for their diuretic and sedative effects, while the infusion of the root was reported to be an emetic [13]. The plant has also been used for its antibacterial, antifungal, and wound-healing effects [19].
This study evaluated the anticancer and immunomodulatory potential of X. spinosum extracts. Results showed that X. spinosum could upregulate the immune system and consequently suppress cancer growth. Based on the results of the antiproliferative study, X. spinosum extract and fractions showed a different magnitude of cytotoxicity against different cancer cell lines, with a high rate of survival in normal cells. Ethanol extract reported the highest effect and suppressed EMT6/P cells at a concentration of 2.57 mg mL−1. Aqueous and Aq. Methanol extracts were also able to reduce cell growth effectively. In agreement with these results, an earlier study has shown that methanol extracts of X. strumarium possess anticancer activity against different cell lines with IC50 values comparable to the values observed in the current study [20,21]. In addition, Romero et al. 2015 reported that xanthatin extraction from X. spinosum has potent cytotoxic and anti-angiogenesis effects [8].
To further understand the mechanism by which X. spinosum extracts exert their effects, the induction of apoptosis was assessed using a caspase-3 activity assay. Apoptosis inhibition is known to be one of the means by which cancer cells assure proliferation and survival. Therefore, apoptosis induction was proposed as an efficient mechanism to oppose cancer cell proliferation. X. spinosum extract and fractions were examined at IC50 values that represent their apoptotic effect, and the results revealed that the aqueous fraction had the highest impact. Caspase-3 activity was enhanced by 2.25 folds compared to the negative control. Other solvent extracts exhibited mild to low apoptotic effects.
The pronounced apoptosis induction could be justified by the high percentage (89.82%) of eupatilin present in ethanol extract. This percentage was calculated based on detected compounds in the extract and cannot be used as an exact value. It showed the availability of Eupatilin at high levels among the detected compounds. Eupatilin is a pharmacologically active flavone that was reported to inhibit cell proliferation and migration and promote apoptosis in earlier studies [22,23]. For example, eupatilin was found to suppress the proliferation of malignant human endometrial cells via the upregulation of the expression of P21 and the induction of G2/M cell cycle arrest [24]. In esophageal cancer, eupatilin was found to prevent proliferation via the inhibition of AKT and mitogen-activated protein kinase (MAPK) signaling pathways [25]. Similarly, eupatilin was found to promote reactive oxygen species production and suppress the AKT signaling pathway in renal cell carcinoma [26]. Furthermore, eupatilin was able to reduce cell proliferation and migration in prostate cancer by increasing the mRNA expression of p53, p21, and p27, which induced cell cycle arrest. As well it has prevented cell migration through the down-regulation of PTEN and NF-KB signaling [27].
The cells and organs that comprise the human immune system function in a complex sequence to provide protection against various pathogens. In our study, we assessed the alteration in both the innate and adaptive immune responses after treating the cells with the extracts from X. spinosum. In the lymphocyte proliferation assay, the n-hexane fraction exhibited the most pronounced stimulation index in the presence and absence of mitogens (LPS and Con-A). Ethanol extract, aq. Methanol fraction and aqueous fraction were effective in stimulating the innate immune response at a concentration of 100 mg mL−1. Such an effect was through the enhancement of macrophage phagocytic activity. The highest enhancing effect was reported for the aq. Methanol extract. It seems that the compound eupatilin identified in a relatively high percentage in the ethanolic extract contributes to the immunomodulatory effect by regulating the function of lymphocytes. Eupatilin was reported to reduce the expression of IL-4, TNF-α, IFN-γ, and IL-1β in a mouse model study [28]. Eupatilin was reported to reduce the expression of IL-4, TNF-α, IFN-γ, and IL-1β in mice model study [28]. Moreover, acteoside showed an immunomodulatory effect. It has significantly reduced TNF- α, IFN- γ, and IL-10 in an animal model study of acute colitis [29].
Since X. spinosum extract and fractions exhibited a significant antiproliferative effect, there was a further investigation in a mouse model implanted with breast cancer. This revealed a reduction in tumor size accompanied by an increased cure percentage. This regression in tumor size might be attributed not only to the presence of eupatilin in ethanol extract but also to other anticancer compounds such as the flavonoids kumatakenin [30] and kaempferide [31] that may exert their therapeutic potential synergistically to suppress cancer progression by enhancing the immune system and promoting apoptosis. Interestingly, recent findings have shown that kumatakenin was able to induce apoptosis of ovarian cancer cells and inhibit the alternative stimulation of macrophages associated with tumors [32]. Kaempferide was also shown to induce apoptosis in cervical cancer cells and activate the caspase cascade [33].
Romero et al. (2015) identified the sesquiterpene lactone xanthatin in the aqueous extract of X. spinosum [8]. The compound has exhibited a noticeable antitumor effect against different cancer cells. For example, xanthatin was reported to inhibit proliferation and promote apoptosis in human breast cancer cells, non-small cell lung cancer cells, and human gastric carcinoma cells [32,33,34]. Such effects agree with the observed activity of the aqueous extract of X. spinosum in this study. The aqueous extract was able to reduce cell growth effectively with an IC50 value of 4.78. Furthermore, it showed the highest fold increase in caspase-3 activity compared to other extracts and fractions. Therefore, it can be concluded that some of the observed effects are attributed to the presence of xanthatin in the aqueous extract.

4. Materials and Methods

4.1. Plant Collection and Extract and Fractions Preparation

X. spinosum was provided by the United Arab Emirates retail. The plant was classified and authenticated by a plant expert in the Royal Society for the Conservation of Nature, Amman, Jordan. After drying the plant at a suitable temperature, it has ground and converted to a powder to ease extract preparation. The plant powder was soaked in 70% ethanol solvent (Laboratory Chemicals, Bernd Kraft GmbH, Duisburg, Germany) in a proportion of one liter per 100 g of the dried powder. Following three days of maceration accompanied by daily stirring, the maceration suspension was filtered and dried utilizing a rotary evaporator. The drying process was enhanced by using a lyophilizer, and then the concentrated ethanol extract was stored at −20 ℃ till used. Ethanol extract fractionation was the next step by using different solvents with various polarity indexes to condense the main phytochemicals based on their polarities. Liquid-liquid fractionation of the ethanol extract was performed using water, aqueous methanol, chloroform, and n-hexane solvents (Laboratory Chemicals, Bernd Kraft GmbH, Germany). The process involved mixing 100 g of ethanol extract with 100 mL of two solvents: chloroform and water and leaving them overnight in a separating funnel. A rotary evaporator was used to evaporate the collected solvents. Afterward, the fractionation method was applied to chloroform fraction using n-hexane and aqueous methanol following the same previous steps. The outcomes of the extraction are ethanol crude extract, along with four fractions (aqueous, chloroform, n-hexane, and aqueous methanol) [35].

4.2. LC-MS Measurements of X. spinosum Ethanol Extract and Fractions

To make the samples ready to use, they dissolved in 2 mL of dimethyl sulfoxide (Scharlab, Barcelona, Spain) and completed the volume to fifty milliliters with acetonitrile (Scharlab, Barcelona, Spain). Centrifugation of the tested samples was carried out at (4000 rpm for 2 min. Then one milliliter was moved to the auto-sampler. The volume that was used to inject the sample was three micro-milliliters. The experiment was achieved utilizing Burker Daltonik (Berman, Germany) impact Ⅱ ESI-Q-TOF system provided with the Burker Dalotonik Elute UPLC system (Beremen, Germany). The apparatus was run using the Ion Source Apollo Ⅱ ion funnel electrospray source (capillary voltage, 2500 v; nebulizer gas, 2 bar; dry gas flow, 8 L min−1; dry temperature, 200 ℃; mass accuracy, less than 1 ppm; mass resolution, 50,000 FRS; the TOF repetition rate, 20 kHz). Chromatographic separation was done using a Burker solo 2-C-18 UHPLC column (100 mm × 2.1 mm × 2 μm) at a flow rate of 0.51 mL min−1 and a column temperature of 40 ℃. The standard of the analysis was applied to detect two parameters: the ms/z and the retention time.

4.3. Animals

Experiments were established using Balb/C female mice with ages around four to six weeks and weights between 21 to 25 g. The animals were kept under specific conditions, including humidity of less than 60% and suitable temperature (25 ℃) with ongoing air ventilation. The Research and Ethical Committee of Applied Science Private University has approved all the murine experiments (Approval Number: 2015-PHA-05). Seventy-six mice were used in this research.

4.4. Cell lines and Cell Culture Conditions

In order to investigate the anti-proliferation activity of X. spinosum extract and fractions, T47D and MCF-7 (human epithelial breast cancer cells) were used, along with EMT6/P (mouse mammary cells) and Vero (kidney epithelial normal cells from African green monkey). The European Collection of Authenticated Cell Cultures (ECACC, Salisbury, UK) is the source of all the cell lines. The normal cell (Vero) was utilized to evaluate the toxicity of X. spinosum extract and fractions in vitro. EMT6/P cells were inoculated into the animals to induct breast tumors in mice. The tested cells were growing in a complete medium and incubated under specific conditions (5% CO₂ and 95% humidity). RPMI 1640 medium (PAN-biotech, Aidenbach, Germany) was used to culture the human breast cancer cells (T47D and MCF-7), while MEM medium (PAN-biotech, Aidenbach, Germany) was used to culture murine breast cancer cells (EMT6/P). For culturing normal cells (Vero), a DMEM medium was applied. The media was supplemented with 1% L-glutamine (Sigma, St. Louis, MO, USA), 10% fetal bovine serum (Gibco, UK), 1% penicillin-streptomycin (Sigma, St. Louis, MO, USA), and 0.1% gentamycin solution (Sigma, St. Louis, MO, USA).

4.5. Anti-Proliferation Assay

The cell viability was detected utilizing a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium (MMT) (Sigma, St. Louis, MO, USA) assay [36]. The tested cells were seeded (15,000 cells/well) into a flat-bottomed 96-well plate. Following 24 h of incubation, X. spinosum was added to the wells at different concentrations (12.5–0.78 mg mL−1), applying the serial dilution method. The treated cells were incubated for 48 h. Afterward, the old media was discarded and replaced with fresh media, along with adding 10 µL of MTT solution to each well and incubated for 3 h at 37 ℃. The DMSO was used to dissolve the formazan crystals by adding 100 µL/well and incubating for another 1 h. The absorbance was measured at 550 nm using a microplate reader. The results were represented by calculating the percentage of survival and IC₅₀ values (the half-maximal inhibitory concentration). The negative control in this experiment is the untreated cells. SPSS was used to estimate the concentration of the IC₅₀ (Equation (1)).
Percentage of Cell Viability (%) = (OD of treated cell/OD of control cell) × 100

4.6. Determination of Apoptosis in EMT6/P Cells

Evaluating caspase-3 expression can reflect the activity of apoptosis within cancer cells. To start with the protocol of the assay kit, cancer cells (EMT6/P) were cultured in 25 cm2 tissue culture flasks with a density of 15,000 cells/mL and incubated for 24 h. Based on the values of the IC₅₀, the concentrations of the X. spinosum extract and fractions were determined. After treating the cells with X. spinosum (ethanol 4.5 mg mL−1, chloroform 9.5 mg/mL, aqueous 13 mg mL−1, aqueous methanol mg mL−1, and n-hexane 10 mg mL−1), the treated cells incubated for 48 h. Afterward, the remaining attached cells were collected and centrifuged, and the cell pellet went under many steps according to the kit instructions (caspase-3 assay kit, Abcam, Cambridge, MA, USA). The absorbance was measured at 405 nm using a microplate reader. The expression of caspase-3 affected by X. spinosum treatment was calculated compared to the result of the negative control [37].

4.7. Acute Toxicity of X. spinosum Extract and Fractions

A limit test was carried out to detect the suitable starting doses in the LD₅₀ estimation assay. Briefly, a group (n = 2) of female mice (age of six weeks and weight around 20–25 g) was treated with X. spinosum extract and fractions (IP injection), with 24 h observation for mortality incidence. If the mice have tolerated the dose, it will increase by 1.5; otherwise, it will reduce by 0.7. The maximum non-lethal and minimum lethal doses presented the lower and upper limits, which were used to prepare LD₅₀ doses [36]. Regarding the LD₅₀ determination assay, three groups (n = 6) of mice have injected with IP with various concentrations. For polar extract and fractions (ethanol, aqueous, and aq. Methanol), the doses were 500, 4000, and 7500 mg kg−1, while for non-polar fractions (chloroform and n-hexane), the doses were 100, 300, and 500 mg kg−1. All the estimated doses were within the higher and lower range determined in the limit test. The conditions of mice were monitored for 24 h. The LD₅₀ was detected by the concentration that exhibited 50% mortality by applying the arithmetical method of Karber [38].

4.8. Antitumor Activity on Experimental Animals

Breast tumor was induced in two groups (n = 7/group) of female Balb/C mice using EMT6/cells in a density of 1 × 105 cells in 0.1 mL. The cells were injected subcutaneously. Following ten days, the developed tumors were measured, and dimensions were recorded. The groups were divided into the control group (n = 7) with no treatment and the five treatment groups (n = 7) with X. spinosum extract and fractions. The estimated dose of ethanol extract represented 10% of the calculated LD₅₀. The treatment stage continued for ten days, and before sacrificing the mice, tumor measurements were recorded. All tumors were extracted and kept in 10% formalin. The volumes of the tumors were recognized using the following formula (2):
Volumes of the tumors   =   A   ×   B 2   ×   0.5
whereas (A) = the length of the longest aspect of the tumor, (B) = the length of the perpendicular to A [39].

4.9. Assessment of Kidney and Liver Functions in Mice

In order to evaluate nephrotoxicity in treated mice, the serum level of creatinine was determined. On the other hand, alanine transaminase (ALT) and aspartate transaminase (AST) were measured to assess liver function. These biomarkers were quantitatively detected by following the instructions of specific kits using DiaSys Respons 920 analyzer (Holzheim, Germany).

4.10. Preparation of Murine Splenocytes

The spleen was extracted from a Balb/C mouse (three Balb/C mice were used in this preparation) and ground under sterilized conditions. Cell suspension of spleen cells was prepared using RPMI-1640 media. After centrifugation, the cells pellet was re-suspended in 5 mL of red blood cells lysis buffer (1 mol L−1 NH4Cl) (ChemCruz, Santa Cruz, CA, USA), with gentle pipetting many times. The suspension was centrifuged for 8 min at 2000 rpm and 4 ℃. RPMI-1640 media was used to re-suspend the splenocytes cells. The splenocytes were ready to be counted and seeded for the study assays.

4.11. Lymphocytes Proliferation Assay

Evaluation of lymphocyte proliferation was achieved based on an MTT-based assay, following a previously described method [40]. The splenocytes suspension (2 × 106 cells/mL) was seeded into a flat-bottomed 96-well plate. Anyway, 5 μg mL−1 of concanavalin (Con A) and 4μg/mL of lipopolysaccharide (LPS) were utilized as mitogens for T and B lymphocytes, respectively. The cells were treated with X. spinosum extract and fractions (25–100 mg mL−1) by adding 100 μL/well from the treatment solution and incubated for 48 h under controlled conditions (5% CO₂ and 37 ℃). Then, 10 μL of MTT solution was added to each well and incubated for 3 h. The final step was adding 100 μL of DMSO to dissolve the formazan particles. The plate was incubated for 1 h to complete the reaction. Using an ELISA microplate reader at 550 nm, the absorbance was measured. The negative control in this experiment was the cells with no treatment. The calculated results were described as the stimulation index compared to the negative control [41].

4.12. Macrophage Isolation from Peritoneal Fluid

Three days before peritoneal macrophages (PEM) harvesting, Balb/C mice were IP injected with 5 mL of 3% (w/v) brewer thioglycollate medium (Laboratory Chemicals, Bernd Kraft GmbH, Germany). Ice-cold sterile phosphate–buffer saline (PBS) (PAN-biotech, Aidenbach, Germany) (pH 7.4) was used to isolate peritoneal macrophages by injecting the PBS into the mouse cavity and recollecting the fluid containing the cells. After centrifugation of the collected fluid for 8 min at 2000 rpm and 4 ℃, the formed pellet was re-suspended in a complete RPMI-1640 medium [42]. In this context, the trypan blue exclusion method was performed to have a suitable cell count for the study assays. By using 100X magnification of a light microscope (Nicon, Japan), clear, bright cells were counted while dark blue cells were excluded. Calculations were carried out to count the number of viable cells in the total sample (Figure 10).

4.13. In Vitro Phagocytic Assay (Nitro Blue Tetrazolium (NBT) Reduction Test

The nitro blue tetrazolium (NBT) reduction assay was carried out based on Rainard’s research [43]. Briefly, peritoneal macrophages (5 × 106 cells/well) were seeded into a 96-well plate accompanied by various concentrations of X. spinosum extract and fractions (25 –100 mg mL−1). The plate was incubated for 48 h at 37 °C. Then each well was treated with 20 μL yeast suspension (5 × 10⁶ cells/well in PBS) and 20 μL nitro blue tetrazolium (NBT) (1.5 mg mL−1 in PBS), except the negative control wells, which received 20 µL PBS and 20 µL DMSO. After incubation for 1 h at 37 ℃, the supernatant was discarded, and the attached macrophages were washed with RPMI 1640. The cells were air-dried before 120 μL of 2M KOH, and 140 μL DMSO was added to each well. The absorbance was measured at 570 nm using an ELISA microplate reader. The percentage of NBT reduction (phagocytic activity) was estimated according to the following Equation (3) [41]:
Phagocytic index = (OD sample − OD control)/OD control × 100

4.14. Determination of Pinocytic Activity Using the Neutral Red Method

Peritoneal murine macrophages were seeded into a flat-bottomed 96-well plate. The cells were treated with X. spinosum using three concentrations (100, 50, and 25 mg mL−1) and then incubated for 48 h at 37 ℃. A neutral red solution (7.5 mg mL−1 in PBS) was added (100 μL) to each well. After incubation for two hours, the supernatant was discarded, and the wells were rinsed with PBS many times to get rid of the remaining particles of the neutral red. Followed by adding 100 μL of cell lysis solution (ethanol and 0.01% acetic acid at the ratio of 1:1) to each well and incubated 24 h at room temperature. At 540 nm, the absorbance was measured using an ELISA microplate reader (BioTek, Highland Park, IL, USA). The pinocytic activity was demonstrated as a pinocytic index. The calculation steps are the same as in the phagocytosis section [43].

4.15. TH1/TH2 Assay

In order to detect the effect of X. spinosum on different cytokines (IFN-γ, IL-2, IL-4, and IL-10), murine splenocytes were cultured with X. spinosum extract, and fractions and immune parameters were determined using mouse uncoated TH1/TH2 ELISA kit (Catalog number 88-7711-44) (Thermo Fisher Scientific, Loughborough, UK). Briefly, murine splenocytes were seeded into a 96-well plate at a concentration of 2 × 106 cells/mL accompanied by adding (1 mg mL−1) of each X. spinosum extract and fractions and left for 48 h incubation under specific conditions (37 ℃ and 5% CO2). After the incubation period, the culture supernatant was collected, and the cytokines level was measured based on the technical procedure mentioned in TH1/TH2 ELISA kit. The concentration (pg mL−1) of each cytokine was determined according to an estimated standard curve for each one.

4.16. Statistical Analysis

Quantitative data were shown as mean ± standard error. The IC₅₀ values obtained with the different concentrations of plant extract were calculated using nonlinear regression in SPSS (Statistical Package for the Social Sciences, Chicago, Illinois version 24). The statistical significance among the groups was determined using SPSS one-way analysis of variance (ANOVA) and student’s t-test. Differences between groups were considered significant when the p-value was less than 0.05 (p < 0.05).

5. Conclusions

In conclusion, the results of this study suggest that X. spinosum shows prominent anticancer and immunomodulatory activities. Such observations are due to the presence of biologically functional compounds in X. spinosum extract and fractions. Further research remains necessary to explicate the mechanism of action of the compounds present in the plant and to explore their therapeutic potential in relation to their clinical efficacy, and to have a better understanding of the apoptosis induction effect. Moreover, more phytochemical analysis is needed to determine the exact concentration of each compound.

Author Contributions

Conceptualization, W.H.T. and L.T.A.K.; methodology, W.H.T., L.T.A.K., and A.I.M.; validation, W.H.T., L.T.A.K., and Z.T.; formal analysis, W.H.T., L.T.A.K., A.I.M., and Z.T.; investigation, W.H.T. and L.T.A.K.; Resources, W.H.T. and L.T.A.K.; data curation, W.H.T., L.T.A.K., A.I.M., and Z.T.; writing—original draft preparation, W.H.T., L.T.A.K., and Z.T.; writing—review and editing, W.H.T., L.T.A.K., A.I.M., and Z.T.; supervision, W.H.T. and L.T.A.K.; project administration, W.H.T. and L.T.A.K.; funding acquisition, W.H.T. and L.T.A.K. All authors have read and agreed to the published version of the manuscript.

Funding

The research was funded by the Zayed University research office, grant number R18036.

Institutional Review Board Statement

The Research and Ethical Committee of Applied Science Private University has approved all the murine experiments (Approval Number: 2015-PHA-05, July 2015).

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article.

Acknowledgments

The authors are thankful to Zayed University, Abu Dhabi, UAE, for the financial support of this research and to Applied Science Private University, Amman, Jordan, for providing laboratory facilities.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Al-Dimassi, S.; Abou-Antoun, T.; El-Sibai, M. Cancer cell resistance mechanisms: A mini review. Clin. Transl. Oncol. Off. Publ. Fed. Span. Oncol. Soc. Natl. Cancer Inst. Mex. 2014, 16, 511–516. [Google Scholar] [CrossRef] [PubMed]
  2. Mathers, C.D.; Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006, 3, e442. [Google Scholar] [CrossRef] [Green Version]
  3. Desai, A.G.; Qazi, G.N.; Ganju, R.K.; El-Tamer, M.; Singh, J.; Saxena, A.K.; Bedi, Y.S.; Taneja, S.C.; Bhat, H.K. Medicinal plants and cancer chemoprevention. Curr. Drug Metab. 2008, 9, 581–591. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Bredel, M. Anticancer drug resistance in primary human brain tumors. Brain Res. Rev. 2001, 35, 161–204. [Google Scholar] [CrossRef]
  5. Pan, S.-Y.; Zhou, S.-F.; Gao, S.-H.; Yu, Z.-L.; Zhang, S.-F.; Tang, M.-K.; Sun, J.-N.; Ma, D.-L.; Han, Y.-F.; Fong, W.-F. New perspectives on how to discover drugs from herbal medicines: CAM’s outstanding contribution to modern therapeutics. Evid.-Based Complement. Altern. Med. 2013, 2013, 627375. [Google Scholar] [CrossRef] [Green Version]
  6. Löve, D.; Dansereau, P. Biosystematic studies on Xanthium: Taxonomic appraisal and ecological status. Can. J. Bot. 1959, 37, 173–208. [Google Scholar] [CrossRef]
  7. Weber, E. Invasive Plant Species of the World: A Reference Guide to Environmental Weeds; CABI: Wallingford, UK, 2017. [Google Scholar]
  8. Romero, M.; Zanuy, M.; Rosell, E.; Cascante, M.; Piulats, J.; Font-Bardia, M.; Balzarini, J.; De Clerq, E.; Pujol, M.D. Optimization of xanthatin extraction from Xanthium spinosum L. and its cytotoxic, anti-angiogenesis and antiviral properties. Eur. J. Med. Chem. 2015, 90, 491–496. [Google Scholar] [CrossRef]
  9. Tetik, F.; Civelek, S.; Cakilcioglu, U. Traditional uses of some medicinal plants in Malatya (Turkey). J. Ethnopharmacol. 2013, 146, 331–346. [Google Scholar] [CrossRef]
  10. Ginesta-Peris, E.; Garcia-Breijo, F.-J.; Primo-Yúfera, E. Antimicrobial activity of xanthatin from Xanthium spinosum L. Lett. Appl. Microbiol. 1994, 18, 206–208. [Google Scholar] [CrossRef]
  11. Kuo, C.L.; Ho, F.M.; Chang, M.Y.; Prakash, E.; Lin, W.W. Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 gene expression by 5-aminoimidazole-4-carboxamide riboside is independent of AMP-activated protein kinase. J. Cell. Biochem. 2008, 103, 931–940. [Google Scholar] [CrossRef]
  12. Amin, S.; Barkatullah, H.K. Pharmacology of Xanthium species. A review. J. Phytopharm. 2016, 5, 126–127. [Google Scholar] [CrossRef]
  13. Khan, M. Traditional Uses of Medicinal Plants Practiced by the Indigenous Communities at Mohmand Agency, FATA, Pakistan. J. Ethnobiol. Ethnomed. 2018, 14, 2. [Google Scholar]
  14. Salinas, A.; De Ruiz, R.; Ruiz, S. sterols, flavonoids, and sesquiterpenic lactones from Xanthium spinosum (Asteraceae). Acta Farm. Bonaer. 1998, 17, 297–300. [Google Scholar]
  15. Raman, G.; Park, K.T.; Kim, J.-H.; Park, S. Characteristics of the completed chloroplast genome sequence of Xanthium spinosum: Comparative analyses, identification of mutational hotspots and phylogenetic implications. BMC Genom. 2020, 21, 855. [Google Scholar] [CrossRef] [PubMed]
  16. Yoon, J.H.; Lim, H.J.; Lee, H.J.; Kim, H.D.; Jeon, R.; Ryu, J.H. Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression by xanthanolides isolated from Xanthium strumarium. Bioorgan. Med. Chem. Lett. 2008, 18, 2179–2182. [Google Scholar] [CrossRef] [PubMed]
  17. Andreani, S.; Paolini, J.; Costa, J.; Muselli, A. Chemical Composition of Essential Oils of Xanthium spinosum L. an Invasive Species of Corsica. Chem. Biodivers. 2017, 14, e1600148. [Google Scholar] [CrossRef]
  18. McQueen, K.; Gottumukkala, V.; Davies, J.F.; Riedel, B. Perioperative implications of the global cancer epidemic. Curr. Anesthesiol. Rep. 2015, 5, 243–249. [Google Scholar] [CrossRef]
  19. Domokos, E.; Kursinszki, L.; Kelemen, H.; Varga, E. Phytopharmacological review of bathurst burr (Xanthium spinosum L.). Acta Pharm. Hung. 2016, 86, 35–40. [Google Scholar]
  20. Kim, Y.S.; Kim, J.S.; Park, S.H.; Choi, S.U.; Lee, C.O.; Kim, S.K.; Kim, Y.K.; Kim, S.H.; Ryu, S.Y. Two cytotoxic sesquiterpene lactones from the leaves of Xanthium strumarium and their in vitro inhibitory activity on farnesyltransferase. Planta Med. 2003, 69, 375–377. [Google Scholar] [CrossRef]
  21. Wang, L.; Wang, J.; Li, F.; Liu, X.; Chen, B.; Tang, Y.X.; Wang, M.K. Cytotoxic sesquiterpene lactones from aerial parts of Xanthium sibiricum. Planta Med. 2013, 79, 661–665. [Google Scholar] [CrossRef] [Green Version]
  22. Kim, M.J.; Kim, D.H.; Na, H.K.; Oh, T.Y.; Shin, C.Y.; Surh, Y.J. Eupatilin, a pharmacologically active flavone derived from Artemisia plants, induces apoptosis in human gastric cancer (AGS) cells. J. Environ. Pathol. Toxicol. Oncol. Off. Organ. Int. Soc. Environ. Toxicol. Cancer 2005, 24, 261–269. [Google Scholar] [CrossRef] [PubMed]
  23. Zhong, W.; Wu, Z.; Chen, N.; Zhong, K.; Lin, Y.; Jiang, H.; Wan, P.; Lu, S.; Yang, L.; Liu, S. Eupatilin Inhibits Renal Cancer Growth by Downregulating MicroRNA-21 through the Activation of YAP1. BioMed Res. Int. 2019, 2019, 5016483. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Cho, J.H.; Lee, J.G.; Yang, Y.I.; Kim, J.H.; Ahn, J.H.; Baek, N.I.; Lee, K.T.; Choi, J.H. Eupatilin, a dietary flavonoid, induces G2/M cell cycle arrest in human endometrial cancer cells. Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc. 2011, 49, 1737–1744. [Google Scholar] [CrossRef] [PubMed]
  25. Wang, X.; Zhu, Y.; Zhu, L.; Chen, X.; Xu, Y.; Zhao, Y.; Shao, Y.; Li, F.; Jiang, Y.; Lu, J.; et al. Eupatilin inhibits the proliferation of human esophageal cancer TE1 cells by targeting the Akt-GSK3β and MAPK/ERK signaling cascades. Oncol. Rep. 2018, 39, 2942–2950. [Google Scholar] [CrossRef] [Green Version]
  26. Zhong, W.F.; Wang, X.H.; Pan, B.; Li, F.; Kuang, L.; Su, Z.X. Eupatilin induces human renal cancer cell apoptosis via ROS-mediated MAPK and PI3K/AKT signaling pathways. Oncol. Lett. 2016, 12, 2894–2899. [Google Scholar] [CrossRef] [Green Version]
  27. Serttas, R.; Koroglu, C.; Erdogan, S. Eupatilin inhibits the proliferation and migration of prostate cancer cells through modulation of PTEN and NF-κB signaling. Anti-Cancer Agents Med. Chem. (Former. Curr. Med. Chem.-Anti-Cancer Agents) 2021, 21, 372–382. [Google Scholar] [CrossRef]
  28. Jung, Y.; Kim, J.C.; Park, N.J.; Bong, S.K.; Lee, S.; Jegal, H.; Jin, L.T.; Kim, S.M.; Kim, Y.K.; Kim, S.N. Eupatilin, an activator of PPARα, inhibits the development of oxazolone-induced atopic dermatitis symptoms in Balb/c mice. Biochem. Biophys. Res. Commun. 2018, 496, 508–514. [Google Scholar] [CrossRef]
  29. Hausmann, M.; Obermeier, F.; Paper, D.H.; Balan, K.; Dunger, N.; Menzel, K.; Falk, W.; Schoelmerich, J.; Herfarth, H.; Rogler, G. In vivo treatment with the herbal phenylethanoid acteoside ameliorates intestinal inflammation in dextran sulphate sodium-induced colitis. Clin. Exp. Immunol. 2007, 148, 373–381. [Google Scholar] [CrossRef]
  30. Woo, J.H.; Ahn, J.H.; Jang, D.S.; Lee, K.T.; Choi, J.H. Effect of Kumatakenin Isolated From Cloves on the Apoptosis of Cancer Cells and the Alternative Activation of Tumor-Associated Macrophages. J. Agric. Food Chem. 2017, 65, 7893–7899. [Google Scholar] [CrossRef]
  31. Nath, L.R.; Gorantla, J.N.; Joseph, S.M.; Antony, J.; Thankachan, S.; Menon, D.B.; Sankar, S.; Lankalapalli, R.S.; Anto, R.J. Kaempferide, the most active among the four flavonoids isolated and characterized from Chromolaena odorata, induces apoptosis in cervical cancer cells while being pharmacologically safe. RSC Adv. 2015, 5, 100912–100922. [Google Scholar] [CrossRef]
  32. Yu, Y.; Yu, J.; Pei, C.G.; Li, Y.Y.; Tu, P.; Gao, G.P.; Shao, Y. Xanthatin, a novel potent inhibitor of VEGFR2 signaling, inhibits angiogenesis and tumor growth in breast cancer cells. Int. J. Clin. Exp. Pathol. 2015, 8, 10355. [Google Scholar] [PubMed]
  33. Zhang, L.; Tao, L.; Ruan, J.; Li, W.; Wu, Y.; Yan, L.; Zhang, F.; Fan, F.; Zheng, S.; Wang, A. Xanthatin induces G2/M cell cycle arrest and apoptosis in human gastric carcinoma MKN-45 cells. Planta Med. 2012, 78, 890–895. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Tao, L.; Cao, Y.; Wei, Z.; Jia, Q.; Yu, S.; Zhong, J.; Wang, A.; Woodgett, J.R.; Lu, Y. Xanthatin triggers Chk1-mediated DNA damage response and destabilizes Cdc25C via lysosomal degradation in lung cancer cells. Toxicol. Appl. Pharmacol. 2017, 337, 85–94. [Google Scholar] [CrossRef]
  35. Talib, W.H.; Mahasneh, A.M. Antiproliferative activity of plant extracts used against cancer in traditional medicine. Sci. Pharm. 2010, 78, 33–46. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Akhila, J.S.; Shyamjith, D.; Alwar, M. Acute toxicity studies and determination of median lethal dose. Curr. Sci. 2007, 93, 917–920. [Google Scholar]
  37. Sabbah, D.A.; Al-Tarawneh, F.; Talib, W.H.; Sweidan, K.; Bardaweel, S.K.; Al-Shalabi, E.; Zhong, H.A.; Abu Sheikha, G.; Abu Khalaf, R.; Mubarak, M.S. Benzoin schiff bases: Design, synthesis, and biological evaluation as potential antitumor agents. Med. Chem. 2018, 14, 695–708. [Google Scholar] [CrossRef]
  38. Talib, W.H.; Mahasneh, A.M. Combination of Ononis hirta and Bifidobacterium longum decreases syngeneic mouse mammary tumor burden and enhances immune response. J. Cancer Res. Ther. 2012, 8, 417–423. [Google Scholar] [CrossRef]
  39. Agrawal, N.; Bettegowda, C.; Cheong, I.; Geschwind, J.-F.; Drake, C.G.; Hipkiss, E.L.; Tatsumi, M.; Dang, L.H.; Diaz, L.A.; Pomper, M. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc. Natl. Acad. Sci. USA 2004, 101, 15172–15177. [Google Scholar] [CrossRef] [Green Version]
  40. Chen, J.-R.; Yang, Z.-Q.; Hu, T.-J.; Yan, Z.-T.; Niu, T.-X.; Wang, L.; Cui, D.-A.; Wang, M. Immunomodulatory activity in vitro and in vivo of polysaccharide from Potentilla anserina. Fitoterapia 2010, 81, 1117–1124. [Google Scholar] [CrossRef]
  41. Boothapandi, M.; Ramanibai, R. Immunomodulatory activity of Indigofera tinctoria leaf extract on in vitro macrophage responses and lymphocyte proliferation. Int. J. Pharm. Pharm. Sci. 2016, 8, 58–63. [Google Scholar]
  42. Liu, Z.; Xing, J.; Huang, Y.; Bo, R.; Zheng, S.; Luo, L.; Niu, Y.; Zhang, Y.; Hu, Y.; Liu, J. Activation effect of Ganoderma lucidum polysaccharides liposomes on murine peritoneal macrophages. Int. J. Biol. Macromol. 2016, 82, 973–978. [Google Scholar] [CrossRef] [PubMed]
  43. Rainard, P. A colorimetric microassay for opsonins by reduction of NBT in phagocytosing bovine polymorphs. J. Immunol. Methods 1986, 90, 197–201. [Google Scholar] [CrossRef] [PubMed]
Figure 1. The antiproliferative activity of X. spinosum extract and its fractions against multiple cell lines (A) T47D breast cancer cells; (B) MCF-7 breasts cancer cells; (C) EMT6/P mouse breast cancer cells and (D) Vero normal cells. The following concentrations were used 0.78 to 12.5 mg mL−1. The percentage survival (%) was obtained as (OD of treated cells/OD of control cells ∗ 100). Results are expressed as means of three independent tests (bars) ± SEM (lines).
Figure 1. The antiproliferative activity of X. spinosum extract and its fractions against multiple cell lines (A) T47D breast cancer cells; (B) MCF-7 breasts cancer cells; (C) EMT6/P mouse breast cancer cells and (D) Vero normal cells. The following concentrations were used 0.78 to 12.5 mg mL−1. The percentage survival (%) was obtained as (OD of treated cells/OD of control cells ∗ 100). Results are expressed as means of three independent tests (bars) ± SEM (lines).
Pharmaceuticals 15 01504 g001aPharmaceuticals 15 01504 g001b
Figure 2. The effect of IC₅₀ concentration of X. spinosum extract and fraction on caspase -3 expression in EMT6/P cell line. The concentration of the extract and fractions: ethanol (2.5 mg mL−1), chloroform (7.5 mg mL−1), aqueous (11 mg mL−1), aqueous methanol (8.1 mg mL−1), and n-hexane (5.5 mg mL−1). Results are expressed as means of three independent experiments (bars)± SEM (lines). (** p <0.001, * p < 0.01 compared to the control).
Figure 2. The effect of IC₅₀ concentration of X. spinosum extract and fraction on caspase -3 expression in EMT6/P cell line. The concentration of the extract and fractions: ethanol (2.5 mg mL−1), chloroform (7.5 mg mL−1), aqueous (11 mg mL−1), aqueous methanol (8.1 mg mL−1), and n-hexane (5.5 mg mL−1). Results are expressed as means of three independent experiments (bars)± SEM (lines). (** p <0.001, * p < 0.01 compared to the control).
Pharmaceuticals 15 01504 g002
Figure 3. A plot demonstrated the changes in average tumor size (mm3) vs. time (days) of treatment with X. spinosum extract and fractions in mice inoculated with the EMT6/P cell line. Tumor size is significant (p < 0.05) compared to the negative control.
Figure 3. A plot demonstrated the changes in average tumor size (mm3) vs. time (days) of treatment with X. spinosum extract and fractions in mice inoculated with the EMT6/P cell line. Tumor size is significant (p < 0.05) compared to the negative control.
Pharmaceuticals 15 01504 g003
Figure 4. Effects of X. spinosum extract and fractions on tumor size and cure percentage. Treatment with X. spinosum resulted in a smaller tumor size and higher cure percentage compared to the negative control (n = 7 mice in each group).
Figure 4. Effects of X. spinosum extract and fractions on tumor size and cure percentage. Treatment with X. spinosum resulted in a smaller tumor size and higher cure percentage compared to the negative control (n = 7 mice in each group).
Pharmaceuticals 15 01504 g004
Figure 5. Effects of X. spinosum extract and fractions on (A) Creatinine (B) ALT and AST serum level after 10 days of treatment. (# p > 0.05) (* p = 0.004) (** p = 0.006) (*** p = 0.03).
Figure 5. Effects of X. spinosum extract and fractions on (A) Creatinine (B) ALT and AST serum level after 10 days of treatment. (# p > 0.05) (* p = 0.004) (** p = 0.006) (*** p = 0.03).
Pharmaceuticals 15 01504 g005aPharmaceuticals 15 01504 g005b
Figure 6. The effect of X. spinosum extract and its fractions on the proliferation of lymphocytes extracted from mouse spleen at the concentration range of (25–100 mg mL−1). (A) In the absence of mitogens); (B) with (4 μg mL−1) of LPS; (C) with (5 μg mL−1) of Con A. Results are summarized as means (bars) ± SEM (lines). Stimulation index = stimulated cells (treated)/non-stimulated cells (control). (* p = 0.005) (** p = 0.01) (*** p = 0.004). The results of the other treated groups were insignificant (p > 0.05) compared to the control.
Figure 6. The effect of X. spinosum extract and its fractions on the proliferation of lymphocytes extracted from mouse spleen at the concentration range of (25–100 mg mL−1). (A) In the absence of mitogens); (B) with (4 μg mL−1) of LPS; (C) with (5 μg mL−1) of Con A. Results are summarized as means (bars) ± SEM (lines). Stimulation index = stimulated cells (treated)/non-stimulated cells (control). (* p = 0.005) (** p = 0.01) (*** p = 0.004). The results of the other treated groups were insignificant (p > 0.05) compared to the control.
Pharmaceuticals 15 01504 g006aPharmaceuticals 15 01504 g006b
Figure 7. In vitro phagocytic assay using nitro blue tetrazolium (NBT) reduction test of peritoneal macrophages treated with various concentrations (25–100 mg mL−1) of X. spinosum extract and fractions. Aqueous methanol fraction had the highest phagocytic index (171). Results are expressed as means (bars) ± SEM (lines). Phagocytic index = (OD sample − OD control)/OD control × 100. (* p = 0.002) (** p = 0.007) (*** p = 0.004).
Figure 7. In vitro phagocytic assay using nitro blue tetrazolium (NBT) reduction test of peritoneal macrophages treated with various concentrations (25–100 mg mL−1) of X. spinosum extract and fractions. Aqueous methanol fraction had the highest phagocytic index (171). Results are expressed as means (bars) ± SEM (lines). Phagocytic index = (OD sample − OD control)/OD control × 100. (* p = 0.002) (** p = 0.007) (*** p = 0.004).
Pharmaceuticals 15 01504 g007
Figure 8. In vitro pinocytic assay using the neutral red method on peritoneal macrophages treated with different concentrations (25–100 mg mL−1) of X. spinosum extract and fractions. N-hexane fraction showed the highest pinocytic index (263). Results are expressed as means of three independent experiments (bars) ± SEM (lines). Phagocytic index = (OD sample − OD control)/OD control × 100. (* p = 0.005) (** p = 0.003).
Figure 8. In vitro pinocytic assay using the neutral red method on peritoneal macrophages treated with different concentrations (25–100 mg mL−1) of X. spinosum extract and fractions. N-hexane fraction showed the highest pinocytic index (263). Results are expressed as means of three independent experiments (bars) ± SEM (lines). Phagocytic index = (OD sample − OD control)/OD control × 100. (* p = 0.005) (** p = 0.003).
Pharmaceuticals 15 01504 g008
Figure 9. The effect of X. spinosum extract and fractions (at a concentration of 1 mg mL−1) on the expression level of different cytokines (pg mL−1). Results are expressed as means of three independent experiments (bars) ± SEM (lines). (* p < 0.05)). Treated groups are compared to the negative control.
Figure 9. The effect of X. spinosum extract and fractions (at a concentration of 1 mg mL−1) on the expression level of different cytokines (pg mL−1). Results are expressed as means of three independent experiments (bars) ± SEM (lines). (* p < 0.05)). Treated groups are compared to the negative control.
Pharmaceuticals 15 01504 g009
Figure 10. Trypan blue exclusion method shows the viable macrophage cells using a light microscope with 100X power of magnification.
Figure 10. Trypan blue exclusion method shows the viable macrophage cells using a light microscope with 100X power of magnification.
Pharmaceuticals 15 01504 g010
Table 1. LC-MS analysis of X. spinosum ethanol extract.
Table 1. LC-MS analysis of X. spinosum ethanol extract.
NOCompoundsFormulaRT
(Retention Time)
Relative % Among Detected Compounds
(Ethanol Extract)
13,5-Dimethoxy-4-hydroxyacetophenoneC10H12O44.320.183
2 SaponarinC27H30O154.980.668
3 AspalathinC21H24O115.270.148
4 GenistinC21H20O105.680.399
5 UmbelliferoneC9H6O36.020.973
6 Naringenin-7-O-glucosideC21H22O106.640.546
7 HexA-Apigenin (or Galangin or Genistein) (PUT)C21H18O116.761.224
8 Apigenin-7-O-glucoside (Apigetrin)C21H20O106.810.980
9 HexA-Chrysoeriol (or Kaempferide) (PUT)C22H20O127.081.244
10 7-Glu Chrysoeriol (NMR)C22H22O117.140.705
11 LuteolinC15H10O68.650.195
12 SorbifolinC16H12O69.070.509
13 ApigeninC15H10O59.930.696
14 HispidulinC16H12O610.350.506
15 EupatilinC18H16O712.5989.824
16 KumatakeninC17H14O614.11.193
Table 2. LC-MS analysis of X. spinosum chloroform fraction.
Table 2. LC-MS analysis of X. spinosum chloroform fraction.
NOCompoundsFormulaRTRelative % Among Detected Compounds
(Chloroform
Fraction)
1 VanillinC8H8O34.10.083
2 (4 or 7) Hydroxy-Coumarin Plus HydrateC9H6O36.010.081
3 HexA-Chrysoeriol (or Kaempferide) (PUT)C22H20O127.130.047
4 7-Glu Chrysoeriol (NMR)C22H22O117.20.050
5 Hydrocinnamic acidC9H10O27.830.049
6 naringeninC15H12O59.520.157
7 5,6,4′-Trihydroxy-7,3′-dimethoxyflavoneC17H14O79.6317.767
8 ApigeninC15H10O59.890.386
9 6,8-Dimethyl-4-hydroxycoumarinC11H10O310.440.050
10 6,8-Dimethyl-4-hydroxycoumarinC11H10O311.510.040
11 3-Oxocostusic acidC15H20O311.90.045
12 EupatilinC18H16O712.4976.839
13 IsobavachinC20H22O414.010.042
14 ZapotininC18H16O615.673.966
15 Pygenic acid BC30H48O518.480.043
16 Glc-Glc-octadecatrienoyl-sn-glycerol (isomer 1) (PUT)C33H56O1420.270.078
17 HederageninC30H48O421.490.063
18 Ursolic acidC30H48O327.980.132
19 y-Linolenic acidC18H30O228.140.074
Table 3. LC-MS analysis of X. spinosum n-hexane fraction.
Table 3. LC-MS analysis of X. spinosum n-hexane fraction.
NOCompoundsFormulaRTRelative % Among Detected Compounds
(n-Hexane
Fraction)
1 ActeosideC29H36O155.934.301
2 BaicaleinC15H10O59.815.670
3 5,6,4′-Trihydroxy-7,3′-dimethoxyflavoneC17H14O710.494.510
4 EupatilinC18H16O712.3985.517
Table 4. LC-MS analysis of X. spinosum aq. Methanol fraction.
Table 4. LC-MS analysis of X. spinosum aq. Methanol fraction.
NOCompoundsFormulaRTRelative % Among Detected Compounds
(Aq. Methanol Fraction)
1 Succinic acidC4H6O40.960.771
2 Chlorogenic acidC16H18O92.020.279
3 4-Hydroxybenzoic acidC7H6O32.380.331
4 4-Hydroxybenzoic acidC7H6O32.530.462
5 SaponarinC27H30O154.560.732
6 ApiinC26H28O144.8331.047
7 Benzoic acidC7H6O25.450.271
8 6,7,3′,4′-TetrahydroxyflavanoneC15H12O65.471.898
9 3-Hydroxy-4-methoxycinnamic acid (isoferulic acid)C10H10O45.473.732
10 Salicylic acidC7H6O35.780.331
11 ActeosideC29H36O155.9248.386
12 HesperidinC28H34O156.10.336
13 Naringenin-7-O-glucosideC21H22O106.511.977
14 NaringinC27H32O146.610.367
15 3′,4′,7-TrihydroxyisoflavoneC15H10O56.780.582
16 HexA-Apigenin (or Galangin or Genistein) (PUT)C21H18O116.793.525
17 HexA-Chrysoeriol (or Kaempferide) (PUT)C22H20O127.114.708
18 BaicaleinC15H10O59.820.256
Table 5. LC-MS analysis of X. spinosum aqueous fraction.
Table 5. LC-MS analysis of X. spinosum aqueous fraction.
NOCompoundsFormulaRTRelative % Among Detected Compounds
(Aqueous
Fraction)
1 2,5-Dihydroxybenzoic acidC7H6O41.70.102
2 4-Hydroxybenzoic acidC7H6O32.521.174
3 Chlorogenic acidC16H18O92.921.662
4 UmbelliferoneC9H6O33.930.546
5 ApiinC26H28O144.8939.604
6 Ferulic acid (trans)C10H10O45.110.202
7 Benzoic acidC7H6O25.290.093
8 Scutellarein-7-glucuronideC21H18O125.865.724
9 3-O-Neohesperidoside Kaempferol (NMR)C27H30O156.140.092
10 3′,4′,7-TrihydroxyisoflavoneC15H10O56.820.280
11 HexA-Apigenin (or Galangin or Genistein) (PUT)C21H18O116.8219.858
12 4-MethylumbelliferoneC10H8O370.698
13 HexA-Chrysoeriol (or Kaempferide) (PUT)C22H20O127.1219.034
14 NaringinC27H32O147.280.186
15 LuteolinC15H10O68.580.124
16 5,6,4′-Trihydroxy-7,3′-dimethoxyflavoneC17H14O79.596.236
17 ApigeninC15H10O59.880.565
18 EupatilinC18H16O79.882.810
Table 6. IC₅₀ values of X. spinosum extract and fractions against different cell lines.
Table 6. IC₅₀ values of X. spinosum extract and fractions against different cell lines.
X. spinosum Extract and FractionsMCF-7
IC₅₀ (mg mL−1) ± SEM
T47D
IC₅₀ (mg mL−1) ± SEM
EMT6/P
IC₅₀ (mg mL−1) ± SEM
Vero
IC₅₀ (mg mL−1) ± SEM
Ethanol extract9.3 ± 0.2512.82 ± 0.242.57 ± 0.24>100
Chloroform fraction7.09 ± 2.339.94 ± 1.237.59 ± 0.11>100
Aqueous fraction4.78 ± 0.2410.83 ± 0.0211.83 ± 0.02>100
Aq. Methanol fraction10.68 ± 0.258.22 ± 0.628.1 ± 0.85>100
n-hexane fraction4.29 ± 2.956.59 ± 0.55.52 ± 1.16>100
Table 7. Acute toxicity assay of X. spinosum ethanol extract, aqueous and aq. Methanol fractions in mice.
Table 7. Acute toxicity assay of X. spinosum ethanol extract, aqueous and aq. Methanol fractions in mice.
Groups (n = 6)Dose (mg/kg)Dose Difference
(a)
Ethanol ExtractAqueous & aq. Methanol Fractions
No. of MortalityMean Mortality (b)Probit (a × b)No. of MortalityMean Mortality (b)Probit
(a × b)
1 5000000000
2 4000350021350010.51750
3 7500350032.58750327000
Mice (n = 6) were injected intraperitoneally and observed for 24 h. n = number of mice in each group. Dose difference (a) = higher dose − lower dose. Mean mortality (b) = (mortality in the second concentration + mortality in the first concentration)/2.
Table 8. Acute toxicity assay of X. spinosum chloroform and n-hexane fractions in mice.
Table 8. Acute toxicity assay of X. spinosum chloroform and n-hexane fractions in mice.
Groups (n = 6)Dose (mg/kg)Dose Difference (a)Chloroform Fractionn-Hexane Fraction
No. of MortalityMean Mortality (b)Probit (a × b)No. of MortalityMean Mortality (b)Probit (a × b)
1 1000000000
2 30020010.510021200
3 5002003240043600
Mice (n = 6) were injected intraperitoneally and observed for 24 h. n = number of mice in each group. Dose difference (a) = higher dose − lower dose. Mean mortality (b) = (mortality in the second concentration + mortality in the first concentration)/2.
Table 9. Effects of X. spinosum extract and fractions on tumor size and cure percentage.
Table 9. Effects of X. spinosum extract and fractions on tumor size and cure percentage.
Treatment Groups (n = 7)Initial
Tumor Size
(mm3) ± SEM
Final Tumor Size
(mm3) ± SEM
% Change in Tumor Size% Of mice with no Detectable TumorNumber of DeathsAverage Tumor Weight (g)
Negative control500.5 ± 8.81043.8 ± 11.1108.522.2%10.73
X. spinosum
ethanol extract
433 ± 7.4306.44 ± 9.8−29.242.8%%00.23
X. spinosum
aqueous fraction
473.9 ± 8.1245.2 ± 12.1−48.228.5%00.54
X. spinosum
Aq. Methanol fraction
482.90 ± 6.4202.6 ± 9.2−58.042.8%00.29
X. spinosum
chloroform fraction
558.6 ± 8.3248.5 ± 10.9−55.557.1%00.39
X. spinosum
n-hexane fraction
499.2 ± 11.5236.1 ± 13.9−52.742.8%00.24
n = 7, mm3: cubic millimeter.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Al Kury, L.T.; Taha, Z.; Mahmod, A.I.; Talib, W.H. Xanthium spinosum L. Extracts Inhibit Breast Cancer in Mice by Apoptosis Induction and Immune System Modulation. Pharmaceuticals 2022, 15, 1504. https://doi.org/10.3390/ph15121504

AMA Style

Al Kury LT, Taha Z, Mahmod AI, Talib WH. Xanthium spinosum L. Extracts Inhibit Breast Cancer in Mice by Apoptosis Induction and Immune System Modulation. Pharmaceuticals. 2022; 15(12):1504. https://doi.org/10.3390/ph15121504

Chicago/Turabian Style

Al Kury, Lina T., Zainab Taha, Asma Ismail Mahmod, and Wamidh H. Talib. 2022. "Xanthium spinosum L. Extracts Inhibit Breast Cancer in Mice by Apoptosis Induction and Immune System Modulation" Pharmaceuticals 15, no. 12: 1504. https://doi.org/10.3390/ph15121504

APA Style

Al Kury, L. T., Taha, Z., Mahmod, A. I., & Talib, W. H. (2022). Xanthium spinosum L. Extracts Inhibit Breast Cancer in Mice by Apoptosis Induction and Immune System Modulation. Pharmaceuticals, 15(12), 1504. https://doi.org/10.3390/ph15121504

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop